Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC May Update

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Pregabalin (Lyrica®) has been accepted for restricted use for the treatment of
peripheral neuropathic pain in adults. The review notes that evidence of efficacy is limited being based upon open-label, uncontrolled, non-randomised studies with small numbers of patients. As such pregabalin is only recommended in patients who have not benefited from or failed to tolerate conventional first and second line treatments.

[Update] This review also recommended that treatment is stopped if the patient has not shown sufficient benefit within 8 weeks of reaching the maximally tolerated therapeutic dose.
Thanks to Rita Shah for reminding me of this point.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC May Update' on Email Share 'SMC May Update' on Delicious Share 'SMC May Update' on Digg Share 'SMC May Update' on Facebook Share 'SMC May Update' on Google+ Share 'SMC May Update' on reddit Share 'SMC May Update' on StumbleUpon Share 'SMC May Update' on Twitter

atomic-wealth

No Comments to “SMC May Update”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,320 spam comments.

atomic-wealth
fond-illness
summer